

# Denis Glotz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/123727/publications.pdf>

Version: 2024-02-01

124  
papers

13,769  
citations

34016

52  
h-index

21474

114  
g-index

136  
all docs

136  
docs citations

136  
times ranked

9210  
citing authors

#	ARTICLE	IF	CITATIONS
1	The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation. <i>Nature Medicine</i> , 2022, 28, 989-998.	15.2	20
2	Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	2.6	40
3	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	3.0	40
4	An activated endothelium after organ transplantation: the pathogenesis of rejection. , 2021, , 69-76.		0
5	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. <i>Transplantation</i> , 2021, 105, 1858-1868.	0.5	3
6	Inflammation Determines the Capacity of Allogenic Endothelial Cells to Regulate Human Treg Expansion. <i>Frontiers in Immunology</i> , 2021, 12, 666531.	2.2	14
7	COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence and Clinical Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2413-2423.	3.0	161
8	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell-mediated and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	2.6	437
9	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	2.6	125
10	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4923.	2.4	191
11	HLA-DQ alloantibodies directly activate the endothelium and compromise differentiation of FoxP3high regulatory T lymphocytes. <i>Kidney International</i> , 2019, 96, 689-698.	2.6	38
12	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. <i>American Journal of Transplantation</i> , 2019, 19, 2865-2875.	2.6	67
13	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. <i>American Journal of Transplantation</i> , 2019, 19, 2876-2888.	2.6	95
14	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	2.6	117
15	Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 625-639.	3.0	48
16	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	2.6	60
17	Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e18-e19.	0.7	7
18	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	2.6	205

#	ARTICLE	IF	CITATIONS
19	Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 606-619.	3.0	53
20	Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 620-635.	3.0	94
21	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	2.6	76
22	The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. <i>American Journal of Transplantation</i> , 2018, 18, 293-307.	2.6	813
23	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	2.6	38
24	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002572.	3.9	76
25	The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice. <i>Frontiers in Immunology</i> , 2018, 9, 106.	2.2	37
26	Prediction of chronic kidney disease after acute kidney injury in ICU patients: study protocol for the PREDICT multicenter prospective observational study. <i>Annals of Intensive Care</i> , 2018, 8, 77.	2.2	8
27	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 3065-3071.	2.6	41
28	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1912-1923.	3.0	208
29	Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. <i>Kidney International</i> , 2017, 92, 729-742.	2.6	43
30	Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 702-715.	3.0	111
31	The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. <i>American Journal of Transplantation</i> , 2017, 17, 28-41.	2.6	551
32	Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin. <i>Frontiers in Immunology</i> , 2017, 8, 1761.	2.2	16
33	C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. <i>American Journal of Transplantation</i> , 2016, 16, 1596-1603.	2.6	110
34	Evidence for an important role of both complement-binding and noncomplement-binding donor-specific antibodies in renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 433-440.	0.8	11
35	Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs. <i>Human Immunology</i> , 2016, 77, 1092-1100.	1.2	23
36	Can solid phase assays be better utilized to measure efficacy of antibody removal therapies?. <i>Human Immunology</i> , 2016, 77, 624-630.	1.2	19

#	ARTICLE	IF	CITATIONS
37	The blurring frontier between autoimmunity and alloimmunity. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 349.	0.8	0
38	Prospective, multicenter, controlled study of quality of life, psychological adjustment process and medical outcomes of patients receiving a preemptive kidney transplant compared to a similar population of recipients after a dialysis period of less than three years – The PreKit-QoL study protocol. <i>BMC Nephrology</i> , 2016, 17, 11.	0.8	18
39	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 293-304.	3.0	244
40	Kidney Allograft Fibrosis After Transplantation From Uncontrolled Circulatory Death Donors. <i>Transplantation</i> , 2015, 99, 409-415.	0.5	15
41	Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer. <i>Transplantation</i> , 2015, 99, 2422-2430.	0.5	16
42	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	3.0	146
43	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1721-1731.	3.0	243
44	Dual Invasive Infection with <i>Phaeoacremonium parasiticum</i> and <i>Paraconiothyrium cyclothyrioides</i> in a Renal Transplant Recipient: Case Report and Comprehensive Review of the Literature of <i>Phaeoacremonium Phaeohyphomycosis</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 2084-2094.	1.8	33
45	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	2.0	41
46	Transplantation R�nale Abo Incompatible. <i>Journal Medical Libanais</i> , 2015, 63, 159-163.	0.0	0
47	Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. <i>BMJ, The</i> , 2014, 349, g6679-g6679.	3.0	252
48	New insights in antibody-mediated rejection. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 597-604.	1.0	41
49	Epitope Analysis of HLA-DQ Antigens. <i>Transplantation</i> , 2014, 98, 157-166.	0.5	68
50	Molecular Microscope Strategy to Improve Risk Stratification in Early Antibody-Mediated Kidney Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2267-2277.	3.0	121
51	Antibody-mediated vascular rejection of kidney allografts: a population-based study. <i>Lancet, The</i> , 2013, 381, 313-319.	6.3	308
52	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. <i>New England Journal of Medicine</i> , 2013, 369, 1215-1226.	13.9	746
53	Diagnostic criteria for kidney transplant rejection: a call to action – Authors' reply. <i>Lancet, The</i> , 2013, 381, 1458-1459.	6.3	2
54	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. <i>Transplantation</i> , 2013, 95, 19-47.	0.5	679

#	ARTICLE	IF	CITATIONS
55	Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score. <i>Journal of Clinical Oncology</i> , 2013, 31, 1302-1309.	0.8	122
56	Kidney graft dysfunction in simultaneous pancreas-kidney recipients after pancreas failure: analysis of early and late protocol biopsies. <i>Clinical Transplantation</i> , 2013, 27, E249-55.	0.8	6
57	Study of the Allogeneic Response Induced by Endothelial Cells Expressing HLA Class II After Lentiviral Transduction. <i>Methods in Molecular Biology</i> , 2013, 960, 461-472.	0.4	7
58	The Seville Expert Workshop for Progress in Posttransplant Lymphoproliferative Disorders. <i>Transplantation</i> , 2012, 94, 784-793.	0.5	45
59	Preliminary results of transplantation with kidneys donated after cardiocirculatory determination of death: a French single-centre experience. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2583-2587.	0.4	44
60	Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: Effects on long-term renal function after liver transplantation. <i>Journal of Hepatology</i> , 2012, 57, 572-576.	1.8	32
61	The role of hypoglycemia induction in kidney transplantation: an update. <i>Clinical Transplantation</i> , 2012, 26, E450-64.	0.8	49
62	Regulation of the CD4+ T cell allo-immune response by endothelial cells. <i>Human Immunology</i> , 2012, 73, 1269-1274.	1.2	20
63	Minimising the clinical impact of the alloimmune response through effective histocompatibility testing for organ transplantation. <i>Transplant Immunology</i> , 2012, 27, 83-88.	0.6	6
64	Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. <i>BJU International</i> , 2012, 109, 195-199.	1.3	43
65	Banff 2011 Meeting Report: New Concepts in Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2012, 12, 563-570.	2.6	379
66	Immunological function of the endothelial cell within the setting of organ transplantation. <i>Immunology Letters</i> , 2011, 139, 1-6.	1.1	36
67	Acute respiratory failure in kidney transplant recipients: a multicenter study. <i>Critical Care</i> , 2011, 15, R91.	2.5	80
68	Pulsatile Perfusion Preservation for Expanded-Criteria Donors Kidneys: Impact on Delayed Graft Function Rate. <i>International Journal of Artificial Organs</i> , 2011, 34, 513-518.	0.7	16
69	Calcineurin Inhibitor-Free Monotherapy in Human Leukocyte Antigen-Identical Live Donor Renal Transplantation. <i>Transplantation</i> , 2011, 91, 330-333.	0.5	11
70	Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil. <i>Transplantation</i> , 2011, 92, 1244-1251.	0.5	24
71	Chronic Interstitial Nephritis in An HIV Type-1-Infected Patient Receiving Ritonavir-Boosted Atazanavir. <i>Antiviral Therapy</i> , 2011, 16, 119-121.	0.6	31
72	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	3.0	88

#	ARTICLE	IF	CITATIONS
73	Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2044-2046.	0.4	45
74	Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2891-2896.	3.3	107
75	Regulatory T Cells in Kidney Allograft Infiltrates Correlate With Initial Inflammation and Graft Function. <i>Transplantation</i> , 2010, 89, 194-199.	0.5	55
76	Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids. <i>Transplantation</i> , 2010, 89, 1511-1517.	0.5	56
77	Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. <i>Transplant International</i> , 2010, 23, 1084-1093.	0.8	68
78	Renal biopsy practice in France: results of a nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3579-3585.	0.4	30
79	What is the relevance of systematic aorto-femoral Doppler ultrasound in the preoperative assessment of patients awaiting first kidney transplantation: a monocentric prospective study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 270-274.	0.4	12
80	A paraneoplastic membranoproliferative glomerulonephritis with isolated C3 deposits associated with hairy cell leukaemia. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2026-2028.	0.4	6
81	Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1398-1406.	3.0	689
82	The evaluation of renal function and disease in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 605-613.	1.8	218
83	Oxidative Stress Mediates a Reduced Expression of the Activating Receptor NKG2D in NK Cells from End-Stage Renal Disease Patients. <i>Journal of Immunology</i> , 2009, 182, 1696-1705.	0.4	53
84	Chronic Kidney Dysfunction in Patients Alive without Relapse 2 Years after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1251-1257.	2.0	56
85	Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus. <i>Transplantation</i> , 2009, 88, 69-76.	0.5	75
86	A Case Report of Adenovirus-Related Acute Interstitial Nephritis in a Patient With AIDS. <i>American Journal of Kidney Diseases</i> , 2008, 51, 121-126.	2.1	16
87	A Simple Clinico-Histopathological Composite Scoring System Is Highly Predictive of Graft Outcomes in Marginal Donors. <i>American Journal of Transplantation</i> , 2008, 8, 2325-2334.	2.6	116
88	Early Epithelial Phenotypic Changes Predict Graft Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1584-1591.	3.0	121
89	Endothelial Cells as Targets of Allograft Rejection. <i>Transplantation</i> , 2006, 82, S19-S21.	0.5	50
90	<i>Candida albicans</i> Arteritis Transmitted by Conservative Liquid After Renal Transplantation: A Report of Four Cases and Review of the Literature. <i>Transplantation</i> , 2006, 82, 1163-1167.	0.5	63

#	ARTICLE	IF	CITATIONS
91	Detection and quantitation of BK virus DNA by real-time polymerase chain reaction in the LT-ag gene in adult renal transplant recipients. <i>Journal of Virological Methods</i> , 2006, 131, 21-27.	1.0	26
92	Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2696-2702.	0.4	11
93	Antidonor Antibodies and Transplantation: How to Deal with Them Before and After Transplantation. <i>Transplantation</i> , 2005, 79, S30-S32.	0.5	19
94	Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. <i>Kidney International</i> , 2005, 67, 2448-2453.	2.6	41
95	Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT). <i>American Journal of Transplantation</i> , 2005, 5, 1120-1129.	2.6	142
96	Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2865-2865.	0.4	13
97	Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. <i>Transplant International</i> , 2004, 17, 1-8.	0.8	61
98	Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. <i>Human Immunology</i> , 2004, 65, 1307-1318.	1.2	23
99	Acute vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d immunofluorescence. <i>Human Pathology</i> , 2004, 35, 385-388.	1.1	12
100	Antibody-Mediated Rejection Criteria - an Addition to the Banff 297 Classification of Renal Allograft Rejection. <i>American Journal of Transplantation</i> , 2003, 3, 708-714.	2.6	960
101	A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1. <i>Transplantation</i> , 2003, 75, 844-851.	0.5	150
102	Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg). <i>American Journal of Transplantation</i> , 2002, 2, 758-760.	2.6	248
103	Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy. <i>Kidney International</i> , 2002, 61, 2176-2186.	2.6	65
104	Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. <i>American Journal of Medicine</i> , 2001, 111, 417-418.	0.6	72
105	INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1. <i>Transplantation</i> , 2001, 72, 1050-1055.	0.5	168
106	Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. <i>Kidney International</i> , 2001, 60, 341-349.	2.6	25
107	Successful endoluminal thrombo-aspiration of renal graft venous thrombosis. <i>Transplant International</i> , 2000, 13, 82-86.	0.8	23
108	T-Cell Suicide Gene Therapy for Organ Transplantation: Induction of Long-Lasting Tolerance to Allogeneic Heart without Generalized Immunosuppression. <i>Molecular Therapy</i> , 2000, 2, 596-601.	3.7	11

#	ARTICLE	IF	CITATIONS
109	Hemolytic Uremic Syndrome: Recurrence after Renal Transplantation. <i>Medicine (United States)</i> , 2000, 79, 90-102.	0.4	39
110	Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells. <i>Human Immunology</i> , 2000, 61, 518-527.	1.2	51
111	PROLONGED ALLOGRAFT SURVIVAL THROUGH CONDITIONAL AND SPECIFIC ABLATION OF ALLOREACTIVE T CELLS EXPRESSING A SUICIDE GENE1. <i>Transplantation</i> , 2000, 69, 2154-2161.	0.5	17
112	Podocytes undergo phenotypic changes and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. <i>Kidney International</i> , 1998, 53, 918-925.	2.6	144
113	Human Immunoglobulins Inhibit Thrombin-induced Ca <sup>2+</sup> Movements and Nitric Oxide Production in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 26473-26476.	1.6	27
114	SUPPRESSION OF HLA-SPECIFIC ALLOANTIBODIES BY HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS (IVIg). <i>Transplantation</i> , 1993, 56, 335-337.	0.5	158
115	Recurrent Acute Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1991, 17, 228-230.	2.1	5
116	Specificity and cross-reactive idiotypes of anti-glomerular basement membrane autoantibodies in HgCl <sub>2</sub> -induced autoimmune glomerulonephritis. <i>European Journal of Immunology</i> , 1990, 20, 93-100.	1.6	40
117	Autoantibody Idiotype and Neonatal B Cell Repertoire. <i>Viral Immunology</i> , 1989, 2, 263-269.	0.6	0
118	Molecular characterization of the VH region of murine autoantibodies from neonatal and adult BALB/c mice. <i>European Journal of Immunology</i> , 1989, 19, 453-457.	1.6	37
119	Idiotype regulation of self responses, autoantibody V regions and neonatal B cell repertoire. <i>Immunology Letters</i> , 1987, 16, 277-282.	1.1	2
120	Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. <i>Molecular Immunology</i> , 1983, 20, 1401-1404.	1.0	52
121	Modulation of the formation of the human C3 amplification convertase of complement by polyelectrolytes. <i>Agents and Actions</i> , 1981, 11, 645-646.	0.7	1
122	Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	0.8	10
123	Surrogate Endpoints for Late Kidney Transplantation Failure. <i>Transplant International</i> , 0, 35, .	0.8	18
124	Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	0.8	6